Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the OPA1 pathway in Autosomal Dominant Optic Atrophy (ADOA): 25 years from gene discovery to therapeutic strategy.

Expert opinion on therapeutic targets - 1 May 2026

Alavi Marcel V

Abstract excerpt

INTRODUCTION: Autosomal Dominant Optic Atrophy (ADOA) is a rare hereditary optic neuropathy primarily caused by OPA1 mutations. Retinal ganglion cell (RGC) loss results in variable visual impairments, occasionally accompanied by extra-ocular manifestations. ADOA also involves a developmental component consistent with OPA1's essential role in mitochondrial fusion, cristae organization, and quality control. As...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Therapy
Share to GTP Phosphohydrolases
Share to Haploinsufficiency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitochondria

Share to Molecular Targeted Therapy

Share to Oligonucleotides, Antisense

Share to Optic Atrophy, Autosomal Dominant

Share to Retinal Ganglion Cells

Source

Identifiers

PMID: 42101483
DOI: 10.1080/14728222.2026.2671678

Genes

OPA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the OPA1 pathway in Autosomal Dominant Optic Atrophy (ADOA): 25 years from gene discovery to therapeutic strategy.PMID 42101483Read ↗

OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets.Semantic proximity Read ↗

Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation.Semantic proximity Read ↗

OPA1: How much do we know to approach therapy?Semantic proximity Read ↗

Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the OPA1 Gene.Semantic proximity Read ↗

Insights on the Genetic and Phenotypic Complexities of Optic Neuropathies.Semantic proximity Read ↗

CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCsSemantic proximity Read ↗

Dominant optic atrophySemantic proximity Read ↗

Mitochondrial optic neuropathies: how two genomes may kill the same cell type?Semantic proximity Read ↗

Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.Semantic proximity Read ↗

The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse.Semantic proximity Read ↗

Rhesus macaques with an OPA1 mutation demonstrate features of autosomal dominant optic atrophy.Semantic proximity Read ↗

A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.